腫瘍内科 抄読会

帝京大学医学部内科学講座 腫瘍内科では、毎週月曜日に、最新のがん医療、がん研究に関するトピックに関する抄読会を開催しています。

ご興味のある方はぜひご参加ください。
お問い合わせ

2020年度 開催記録

日付 担当 論文タイトル 掲載雑誌
7月20日 丹澤  Pembrolizumab or Placebo Plus Etoposide
and Platinum as First-Line Therapy for
Extensive-Stage Small-Cell Lung Cancer:
Randomized, Double-Blind, Phase III
KEYNOTE-604 Study
 J Clin Oncol 38:2369-2379.
8月3日 春山 Treatment Decisions for Advanced Non‑Squamous Non‑Small Cell
Lung Cancer: Patient and Physician Perspectives on Maintenance
Therapy
Patient. 2019 Apr;12(2):223-233.
8月24日 研修医1年 症例報告
9月14日 落合 Necitumumab plus gemcitabine and cisplatin versus gemcitabine and
cisplatin alone as first-line treatment for stage IV squamous non-small cell
lung cancer: A phase 1b and randomized, open-label, multicenter, phase 2
trial in Japan
Lung Cancer 129 (2019) 55–62
10月5日 風張 内科地方会予演会
10月19日 研修医1年
11月2日 市川 肺癌学会予演会

2019年度 開催記録

日付 担当 論文タイトル 掲載雑誌
4月1日 オリエンテーション
4月8日 本田 Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective,
pharmacovigilance study
Lancet Oncol 2018; 19: 1579–89
4月15日 研修医1年①星野 Overall Survival with Fulvestrant plus
Anastrozole in Metastatic Breast Cancer
N Engl J Med 2019;380:1226-34.
4月22日 研修医1年②平田 Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label,
randomised, multicentre, phase 3 trial
Lancet Oncol 2019 May;20(5):625-635.
5月13日 上松先生の講義 EGFR-TKIの爪囲炎のケア
5月27日 太田 Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised,open-label, controlled, phase 3 trial Lancet 2019; 393: 1819–30
6月3日 坂本 Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-quamous non-small-cell lung cancer (IMpower130):
a multicentre, randomised, open-label, phase 3 trial
Lancet Oncol 2019
Published Online
May 20, 2019
6月10日 渡邊 Association of Patient Characteristics and Tumor Genomics
With Clinical Outcomes Among Patients With Non–Small Cell
Lung Cancer Using a Clinicogenomic Database
JAMA. 2019;321(14):1391-1399.
6月17日 田上 Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study J Clin Oncol. 2019 Jun 2:JCO1900934
6月24日 研修医1年 風張 Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2):a multicentre, open-label, randomised, non-comparative,phase 2 trial Lancet Oncol 2019; 20: 239–53
7月1日 落合予演会
7月8日 市川 ASCO報告
7月29日 石原 Outcome of Patients with Non–Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors Journal of Thoracic Oncology Vol. 14 No. 7: 1244-1254
8月5日 丹澤 ASCO報告
8月26日 研修医1年中島 First-Line Nivolumab Plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer (CheckMate 568):Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers J Clin Oncol 37:992-1000.
9月2日 春山 Efficacy of Prophylactic Treatment for Oxycodone-Induced Nausea
and Vomiting Among Patients with Cancer Pain (POINT): A
Randomized, Placebo-Controlled, Double-Blind Trial
TheOncologist 2017;22:1–8
10月7日 落合 Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small cell lung cancer receiving 1st-line chemotherapy: a Phase 1b/randomized Phase 2 trial Ann Oncol. 2019 Aug 27.
10月21日 本田 Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non–Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional,
Phase II, Randomized Study
J Clin Oncol 37:1558-1565.
11月25日 研修医2年 青木 Association between waist circumference and risk of
colorectal neoplasia in normal-weight adults
J Gastroenterol Hepatol. 2019 Jun 27.
12月2日 太田 Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled,open-label, phase 3 trial Lancet. 2019 Oct 4. pii: S0140-6736(19)32222-6
12月23日 研修医1年 菅 Trifluridine/tipiracil versus placebo in patients with heavily
pretreated metastatic gastric cancer (TAGS): a randomised,
double-blind, placebo-controlled, phase 3 trial
Lancet Oncol. 2018 Nov;19(11):1437-1448.
1月27日 市川 Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3):a multicentre, randomised, open-label, phase 3 trial Lancet. 2019 Oct 4. pii: S0140-6736(19)32222-6.
2月3日 坂本 Atezolizumab and Nab-Paclitaxel
in Advanced Triple-Negative Breast Cancer
N Engl J Med 2018;379:2108-21.
2月10日 渡邊 Cumulative Burden of Colorectal Cancer-Associated Genetic Variants is More Strongly Associated With Early-onset vs Late-onset Cancer Gastroenterology. 2019 Dec 19. pii: S0016-5085(19)41937-9

2018年度 開催記録

日付 担当 論文タイトル 掲載雑誌
4月2日 オリエンテーション
4月23日 研修医1年

(田代)

S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal
cancer (TRICOLORE): a randomized, open-label, phase
III, noninferiority trial
Annals of Oncology 29: 624–631, 2018
5月7日 臨床研究読み合わせ
5月14日 市川  Atezolizumab versus docetaxel in patients with previously
treated non-small-cell lung cancer (OAK): a phase 3,
open-label, multicentre randomised controlled trial
 Lancet 2017; 389: 255–65
5月21日 本田  Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
6月4日 太田  Pembrolizumab plus Chemotherapy
in Metastatic Non–Small-Cell Lung Cancer
 N Engl J Med 2018; 378:2078-2092
6月11日 深澤  予演会
6月18日 坂本  予演会
6月25日 研修医1年(村川)  Neoadjuvant PD-1 Blockade
in Resectable Lung Cancer
 published on April 16,2018, at NEJM
DOI: 10.1056/NEJMoa1716078
7月2日
7月9日 太田・深澤  臨床腫瘍学会予演会
7月30日 研修医2年(安田)  Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial.  Lancet, Vol: 392, Issue: 10142, Page: 123-133,2018.
8月6日  渡邊 Breast cancer in young women: do BRCA1 or BRCA2 mutations matter?

 

Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study

Lancet Oncol. 2018 Feb;19(2):150-151

 

 

Lancet Oncol 2018; 19: 169–80

8月13日  石原  Improvement in Overall Survival in a Randomized Study That
Compared Dacomitinib With Gefitinib in Patients With
Advanced Non–Small-Cell Lung Cancer and EGFRActivating
Mutations
 J Clin Oncol2018; 36:2244-2250.
8月20日  丹澤  Modified XELIRI (capecitabine plus irinotecan) versus
FOLFIRI (leucovorin, fluorouracil, and irinotecan), both
either with or without bevacizumab, as second-line therapy
for metastatic colorectal cancer (AXEPT): a multicentre,
open-label, randomised, non-inferiority, phase 3 trial
 Lancet Oncol 2018; 19: 660–71
8月27日 研修医1年(小山)  Atezolizumab for First-Line Treatment
of Metastatic Nonsquamous NSCLC
 N Engl J Med 2018;378:2288-301.
9月10日  春山  Edoxaban for the Treatment of Cancer-
Associated Venous Thromboembolism
 N Engl J Med 2018;378:615-24.
10月1日  落合  Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer  N Engl J Med 2018;378:113-25.
10月15日 本田  Effects of Surgery With Salvage Stereotactic Radiosurgery Versus Surgery With Whole-Brain Radiation Therapy in
Patients With One to Four Brain Metastases (JCOG0504): A Phase III, Noninferiority, Randomized Controlled Trial
 J Clin Oncol. 2018 Jun 20:JCO2018
10月22日 研修医1年(小野)  Overall Survival with Durvalumab
after Chemoradiotherapy in Stage III NSCLC
 N Engl J Med. 2018 Sep 25.
10月29日 研修医1年
11月5日  太田  Lorlatinib in non-small-cell lung cancer with ALK or ROS1rearrangement: an international, multicentre, open-label,
single-arm first-in-man phase 1 trial
 Lancet Oncol 2017; 18: 1590–99
11月12日  予演会
11月19日 石原 CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in
Patients With Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
 J Clin Oncol. 2018 Aug 28
11月26日 研修医2年(鈴木)  Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer  N Engl J Med. 2018 Oct 21
12月3日 坂本  Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer  N Engl J Med 2018;379:2027-39.
12月10日 研修医1年(寺島)  Pembrolizumab plus Chemotherapy
for Squamous Non–Small-Cell Lung Cancer
 N Engl J Med 2018;379:2040-51.
12月17日 研修医1年(中川)  Atezolizumab and Nab-Paclitaxel
in Advanced Triple-Negative Breast Cancer
 N Engl J Med 2018;379:2040-51.
1月7日  春山  First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer  N Engl J Med 2018;379:2220-9.
1月21日  市川  Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in
Patients With Non–Small-Cell Lung Cancer
 J Clin Oncol 36:2872-2878.
1月28日  研修医2年(石渡)  Pembrolizumab versus methotrexate, docetaxel, or
cetuximab for recurrent or metastatic head-and-neck
squamous cell carcinoma (KEYNOTE-040): a randomised,
open-label, phase 3 study
 Lancet 2019; 393: 156–67
2月4日  渡邊  Maintenance Olaparib in Patients with Newly Diagnosed
Advanced Ovarian Cancer
 N Engl J Med 2018;379:2495-505
2月18日 研修医1年(計田)  Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung
cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
 Lancet Oncol 2017; 18: 1454–66
2月25日 研修医1年(服部)  Apixaban to Prevent Venous Thromboembolism
in Patients with Cancer
 N Engl J Med. 2019 Feb 21;380(8):711-719.
3月4日  予演会
3月11日  丹澤  Overall Survival with Palbociclib and
Fulvestrant in Advanced Breast Cancer
N Engl J Med 2018;379:1926-36.

2017年度 開催記録

日付

担当

論文タイトル

掲載雑誌

4月3日

 オリエンテーション

4月17日

研修医(金城)

Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre,
randomised, open-label, phase 3 trial
 Lancet Oncol. 2017 May;18(5):663-671. 

4月24日

研修医(林)

Osimertinib or Platinum–Pemetrexed
in EGFR T790M–Positive Lung Cancer
 N Engl J Med 2017;376:629-40.

5月1日

太田(真)

 First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study  Lancet 2017; 389: 917–29

5月8日

坂本

Management of Brain Metastases in Tyrosine Kinase Inhibitor–Na¨ıve Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer: A Retrospective Multi-
Institutional Analysis
 J Clin Oncol 35:1070-1077.

5月15日

市川

Use of chemotherapy near the end of life: what
factors matter?
 Ann Oncol. 2017 Apr 1;28(4):809-817. 

5月22日

渡邊  Developing Canadian oncology education goals and objectives for medical students: a national modified Delphi study  CMAJ Open. 2016 Jul 14;4(3):E359-E364.

5月29日

臼井

Carboplatin and pemetrexed with or without
pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label
KEYNOTE-021 study
 Lancet Oncol. 2016 Nov;17(11):1497-1508

6月5日

石原

 Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy  J Clin Oncol. 2017 Mar;35(7):709-717

6月12日

丹澤

 Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation  N Engl J Med. 2017 Jun 4.

6月19日

深澤

 予演会

6月26日

研修医(鈴木)

 Tissue Factor As a Predictor of Recurrent Venous Thromboembolism in Malignancy: Biomarker Analyses of the CATCH Trial  J Clin Oncol. 2017 Apr 1;35(10):1078-1085.

7月10日

 市川  臨床腫瘍学会予演会

7月24日

予演会

7月31日

本田 Toxicity of concurrent stereotactic radiotherapy and targeted therapy
or immunotherapy: A systematic review
 Cancer Treatment Reviews 53 (2017) 25–37

8月7日

春山  A prospective multicentre study to evaluate the efficacy and tolerability of osmotic release oral system (OROS®) hydromorphone in opioid-naive cancer patients:Results of the Korean South West Oncology Group study Pain Res Manag Vol 20 No 6
November/December 2015

8月14日

 太田  Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial  Lancet Oncol 2017; 18: 895–903

8月21日

研修医2年(落合) Phase IIb, Randomized, Double-Blind, Placebo-Controlled
Study of Naldemedine for the Treatment of Opioid-Induced
Constipation in Patients With Cancer
 J Clin Oncol 35:1921-1928

8月28日

研修医1年(田村)

Nivolumab for Recurrent Squamous-Cell
Carcinoma of the Head and Neck
 N Engl J Med 2016;375:1856-67.

9月4日

 坂本  First report of eribulin in combination with pertuzumab and trastuzumab for advanced HER2-positive breast cance  The Breast 35 (2017) 78e84

9月11日

 渡邊  Guideline-Based Statin Eligibility, Cancer Events, and NoncardiovascularMortality in the Framingham Heart Study  J Clin Oncol 35:2927-2933.

9月25日

 臼井  ミニレクチャー

10月2日

 石原  内科学会地方会予演会

10月23日

 丹澤  Durvalumab after Chemoradiotherapy
in Stage III Non–Small-Cell Lung Cancer
 N Engl J Med 2017; 377:1919-1929

10月30日

研修医1年(森田)

 Statin Use After Diagnosis of Colon Cancer and Patient Survival Gastroenterology 2017;153:470–479

11月6日

 深澤  予演会

11月13日

 太田  Association Between EGFR T790M Status and
Progression Patterns During Initial EGFR-TKI
Treatment in Patients Harboring EGFR Mutation
 Clinical Lung Cancer, Vol. 18, No. 6, 698-705

11月20日

 本田  Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis:
exploratory results from a randomised, double-blind,placebo-controlled trial
 Lancet 2017; 390: 1833–42

11月27日

研修医2年(安川)  Randomized Trial of Low-Dose Morphine Versus Weak
Opioids in Moderate Cancer Pain
 J Clin Oncol 34:436-442. 2015

12月4日

 市川  Osimertinib in Untreated EGFR-Mutated
Advanced Non–Small-Cell Lung Cancer
 published on November18, 2017, at NEJM.

12月11日

 坂本  Randomized controlled trial of S-1 versus docetaxel
in patients with non-small-cell lung cancer previously
treated with platinum-based chemotherapy
(East Asia S-1 Trial in Lung Cancer)
 Annals of Oncology 28: 2698–2706, 2017

12月18日

 春山 Comparative clinical effects of hydromorphone
and morphine: a meta-analysis
 British Journal of Anaesthesia 107 (3): 319–28 (2011)

12月25日

研修医1年(佐山)

 Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.  Lancet. 2017 Dec 2;390(10111):2461-2471.

1月15日

 渡邊  Long-term outcomes for neoadjuvant versus adjuvant
chemotherapy in early breast cancer: meta-analysis of
individual patient data from ten randomised trials
 Lancet Oncol 2018; 19: 27–39

1月22日

 臼井  Long-term Outcome of Surgery or Stereotactic
Radiotherapy for Lung Oligometastases
 Journal of Thoracic Oncology Vol. 12 No. 9: 1442-1445

1月29日

石原  Adjuvant chemotherapy with or without bevacizumab in
patients with resected non-small-cell lung cancer (E1505):
an open-label, multicentre, randomised, phase 3 trial
Lancet Oncol 2017; 18: 1610–23

2月5日

 丹澤  HALO 202: Randomized Phase II Study of PEGPH20 Plus
Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/
Gemcitabine in Patients With Untreated, Metastatic
Pancreatic Ductal Adenocarcinoma
 J Clin Oncol 36:359-366.

2月19日

 研修医2年(落合)  予演会

2月26日

研修医1年(友寄)  Once-a-Week Versus Once-Every-3-Weeks Cisplatin
Chemoradiation for Locally Advanced Head and Neck
Cancer: A Phase III Randomized Noninferiority Trial
 J Clin Oncol. 2017 Dec 8:JCO2017749457.

3月5日

 春山  Effect of Duloxetine on Pain, Function,
and Quality of Life Among Patients
With Chemotherapy-Induced
Painful Peripheral Neuropathy
 JAMA, April 3, 2013—Vol 309, No. 13

2016年度 開催記録

日付

担当

論文タイトル

掲載雑誌

4月4日

 オリエンテーション

4月11日

夏目

 Preferences of Advanced Cancer Patients for Communication

on Anticancer Treatment Cessation and the Transition to

Palliative Care

 Cancer 2015;121:4240-9

4月18日

坂本

Influence of the Acidic Beverage Cola on the Absorption of Erlotinib in Patients With Non–Small-Cell Lung Cancer

JCO Apr 20, 2016:1292-1294

4月25日

研修医1年

(三須)

Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L

JCO.2015.63.4154

5月2日

渡邊

Multicenter Cohort Study on the Survival Time of Cancer Patients Dying at Home or in a Hospital:Does Place Matter?

 Cancer 2016;122:1453-60

5月9日

本田

救急勉強会①

5月16日

救急勉強会②

5月23日

市川

臨床試験

5月30日

深澤

 A Novel Multivariate Index for Pancreatic

Cancer Detection Based On the Plasma Free Amino Acid Profile

 PLoS One. 2015 Jul 2;10(7):e0132223

6月6日

夏目

Early administration of epinephrine (adrenaline) in patients

with cardiac arrest with initial shockable rhythm in hospital:

propensity score matched analysis

BMJ. 2016 Apr 6;353:i1577

6月13日

太田

Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled,phase 3 study

Lancet 2016; 387: 968–77

6月20日

研修医2年

(落合)

 PROCLAIM: Randomized Phase III Trial of Pemetrexed-

Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation

Therapy Followed by Consolidation Chemotherapy in Locally

Advanced Nonsquamous Non–Small-Cell Lung Cancer

 J Clin Oncol. 2016 Mar 20;34(9):953-62

6月27日

研修医1年

(竹下)

Pembrolizumab versus docetaxel for previously treated,PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

 Lancet 2016; 387: 1540–50

7月4日

坂本

 EGFR‑TKI rechallenge with bevacizumab in EGFR‑mutant

non‑small cell lung cancer

 Cancer Chemother Pharmacol. 2015 Oct;76(4):835-41

7月11日

深澤

予演会

8月1日

臼井

8月8日

夏目

Impact of bevacizumab in combination with erlotinib on
EGFR-mutated non–small cell lung cancer xenograft models
with T790M mutation or MET amplification
 Int. J. Cancer: 138, 1024–1032 (2016)

8月15日

研修医1年

(安川)

Olanzapine for the Prevention of
Chemotherapy-Induced Nausea and Vomiting
 N Engl J Med 2016;375:134-42.

8月22日

渡邊

Facilitation of Drug Transport across the Blood–Brain Barrier
with Ultrasound and Microbubbles
 Pharmaceutics 2015, 7, 275-293

8月29日

医局会

9月12日

医局会

9月26日

本田

PROCLAIM: Randomized Phase III Trial of Pemetrexed-
Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation
Therapy Followed by Consolidation Chemotherapy in Locally
Advanced Nonsquamous Non–Small-Cell Lung Cancer
 J Clin Oncol 2016; 34:953-962.

10月3日

太田

 Combined chemotherapy with cisplatin, etoposide, andirinotecan versus topotecan alone as second-line treatment
for patients with sensitive relapsed small-cell lung cancer
(JCOG0605): a multicentre, open-label, randomised
phase 3 trial
 Lancet Oncol 2016; 17: 1147–57

10月17日

深澤

A Correlative Biomarker Analysis of the Combination of Bevacizumab and Carboplatin-Based Chemotherapy for
Advanced Nonsquamous Non–Small-Cell Lung Cancer Results of the Phase II Randomized ABIGAIL Study (BO21015)
 Journal of Thoracic Oncology 2014; 9(6):848-855

10月24日

研修医1年

(本田)

 Five-year survival in EGFR-mutant metastatic lung adenocarcinoma treated with EGFR-TKIs  J Thorac Oncol. 2016 April ; 11(4): 556–565.

10月31日

研修医2年

(松本)

Pembrolizumab versus Chemotherapy for
PD-L1–Positive Non–Small-Cell Lung Cancer
 N Engl J Med. 2016 Oct 8. [Epub ahead of print]

11月7日

市川

 Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016 Oct 24.
pii: S1470-2045(16)30532-0

11月14日

坂本

 Re-biopsy status among non-small cell lung cancer patients in Japan: A retrospective study  Lung Cancer. 2016 Nov;101:1-8.

11月21日

深澤(予演会)

11月28日

研修医2年

(大野)

Ramucirumab versus placebo in combination with secondline FOLFIRI in patients with metastatic colorectal carcinoma
that progressed during or after fi rst-line therapy with bevacizumab, oxaliplatin, and a fl uoropyrimidine (RAISE):
a randomised, double-blind, multicentre, phase 3 study
 Lancet Oncol 2015; 16: 499–508

12月5日

 渡邊  30-day mortality after systemic anticancer treatment for breast and lung cancer in England: a population-based,observational study  Lancet Oncol 2016; 17: 1203–16

12月12日

 臼井 United States Health Care Reform
Progress to Date and Next Steps
 JAMA. 2016;316(5):525-532.

12月26日

研修医1年

(磯崎)

Association Between Palliative Care
and Patient and Caregiver Outcomes
A Systematic Review and Meta-analysis
 JAMA. 2016;316(20):2104-2114.

1月23日

研修医2年

(豊田)

 予演会

1月30日

研修医2年

(春山)

 予演会

2月6日

石原  Outcome in patients with small cell lung cancer re-irradiated for brainmetastases after prior prophylactic cranial irradiation  Lung Cancer 101 (2016) 76–81

2月13日

 本田  Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial  Lancet 2016; 388: 2004–14

2月20日

プロトコール読み合わせ

2月27日

研修医1年

(水川)

 Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON):an international, randomised, double-blind, phase 3 trial  Lancet 2016; 388: 2997–3005

3月6日

 太田(修)

3月13日

 太田(真)

3月27日

 深澤

 

2015年度 開催記録

日付 担当 論文タイトル 掲載雑誌
4月6日

内科学会予演会

4月13日

呼吸器学会予演会

4月20日

本田

Phase 3 Trials of Stereotactic Radiosurgery With or Without Whole-Brain Radiation Therapy for 1 to 4 Brain Metastases: Individual Patient
Data Meta-Analysis

Int J Radiat Oncol Biol Phys. 2015 Mar 15;91(4):710-7

4月27日

研修医1年

(曽根Dr)

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung c ancer (CheckMate 063):
a phase 2, single-arm trial

Lancet Oncol 2015; 16: 257–65

5月11日

学位論文研究報告

5月18日

太田

Initial Therapy with FOLFOXIRI and
Bevacizumab for Metastatic Colorectal Cancer

N Engl J Med 2014;371:1609-18.

5月25日

深澤

Bevacizumab Combined With Chemotherapy for Platinum-
Resistant Recurrent Ovarian Cancer: The AURELIA Open-
Label Randomized Phase III Trial

JCO May 1, 2014 vol. 32 no. 13 1302-1308

6月1日

坂本

Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial

Lanset  Volume 16, Issue 6, June 2015, Pages 619–629

6月8日

Dr. Thang

6月15日

夏目

Primary chemotherapy versus primary surgery for newly
diagnosed advanced ovarian cancer (CHORUS): an open-label,
randomised, controlled, non-inferiority trial

The Lancet, In Press, Corrected Proof, Available online 19 May 2015

6月22日

研修医1年

(吉津Dr)

AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell
Lung Cancer

N Engl J Med 2015;372:1689-99.

7月13日

深澤 T-MOC予演会

7月27日

研修医2年

(菊山Dr)

Pembrolizumab for the Treatment
of Non–Small-Cell Lung Cancer

8月3日

ASCO報告(市川)

8月17日

ASCO報告(丹澤)

8月24日

深澤 予演会

8月31日

研修医1年

(大野Dr)

Pembrolizumab for the Treatment
of Non–Small-Cell Lung Cancer

N Engl J Med 2015;372:2018-28.

9月7日

渡邊

Obesity paradox in cancer: new insights provided by body
composition1–3

Am J Clin Nutr 2014;99:999–1005

9月14日

本田

Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials

Lancet Oncol 2015; 16: 630–37

9月28日

内科学会 地方会予演会 夏目

10月19日

太田

Use of thoracic radiotherapy for extensive stage small-cell
lung cancer: a phase 3 randomised controlled trial

Lancet 2015; 385: 36–42

10月26日

研修医1年

(西澤Dr)

Effect of Duloxetine on Pain, Function,
and Quality of Life Among Patients
With Chemotherapy-Induced
Painful Peripheral Neuropathy

JAMA, April 3, 2013—Vol 309, No. 13

11月2日

深澤

Screening for Occult Cancer in Unprovoked Venous
Thromboembolism

N Engl J Med 2015;373:697-704.

11月9日

市川

Impact of Specific Epidermal Growth Factor Receptor
(EGFR) Mutations and Clinical Characteristics on
Outcomes After Treatment With EGFR Tyrosine Kinase
Inhibitors Versus Chemotherapy in EGFR-Mutant Lung
Cancer: A Meta-Analysis

JCO June 10, 2015 vol. 33
no. 17 1958-1965

12月14日

丹澤

 RECIST progression patterns during EGFR tyrosine kinase inhibitor treatment of advanced non-small cell lung cancer patients harboring an EGFR mutation.  Volume 90, Issue 3, December 2015, Pages 477–483

12月21日

渡邊

Patient-Reported Outcomes and Quality of Life in PROFILE
1007: A Randomized Trial of Crizotinib Compared with
Chemotherapy in Previously Treated Patients with
ALK-Positive Advanced Non–Small-Cell Lung Cancer
 J Thorac Oncol. 2014;9: 1625–1633

12月28日

研修医1年

(熊木Dr)

 Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study  J Clin Oncol. 2015 Nov 10;33(32):3781-7.

1月4日

深澤

 Sensitivity and specifi city of mammography and adjunctive
ultrasonography to screen for breast cancer in the Japan
Strategic Anti-cancer Randomized Trial (J-START):
a randomised controlled trial
 Lanset.Volume 387, No. 10016, p341–348, 23 January 2016

1月25日

斉藤

 Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients  J Thorac Oncol. 2015;10: 1437–1443

2月1日

本田

Bevacizumab for newly diagnosed pleural mesothelioma in
the Mesothelioma Avastin Cisplatin Pemetrexed Study
(MAPS): a randomised, controlled, open-label, phase 3 trial
The Lancet, Available online 21 December 2015,

2月15日

市川

Docetaxel plus nintedanib versus docetaxel plus placebo in
patients with previously treated non-small-cell lung cancer
(LUME-Lung 1): a phase 3, double-blind, randomised
controlled trial
 Lancet Oncol 2014; 15: 143–55

2月29日

研修医1年

Perioperative Bridging Anticoagulation
in Patients with Atrial Fibrillation
 N Engl J Med 2015;373:823-33.

3月28日

丹澤  First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases.  J Thorac Oncol. 2016 Mar;11(3):380-90

2014年度 開催記録

日付 担当 論文タイトル 掲載雑誌
4月28日 研修医(岩田) Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations JCO 2013 31(27) 3327-3334
5月12日 本田 Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
vs Conventional Chemotherapy in Non–Small Cell Lung Cancer
Harboring Wild-Type Epidermal Growth Factor Receptor
AMeta-analysis
JAMA. 2014;311(14):1430-1437.
5月19日 Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer N Engl J Med 2014;370:1189-97.
5月26日 丹澤 Ramucirumab monotherapy for previously treated advanced
gastric or gastro-oesophageal junction adenocarcinoma
(REGARD): an international, randomised, multicentre,
placebo-controlled, phase 3 trial
Lancet 2014; 383: 31–39
6月2日 深澤 Reappraisal of Short-term Low-volume Hydration in Cisplatin-based
Chemotherapy: Results of a Prospective Feasibility Study in
Advanced Lung Cancer in the Okayama Lung Cancer Study Group
Trial 1002
Jpn J Clin Oncol 2013;43(11)1115–1123
6月9日 太田 Ramucirumab monotherapy for previously treated advanced
gastric or gastro-oesophageal junction adenocarcinoma
(REGARD): an international, randomised, multicentre,
placebo-controlled, phase 3 trial
Lancet 2014; 383: 31–39
6月16日 坂本 TAS-102 monotherapy for pretreated metastatic colorectal
cancer: a double-blind, randomised, placebo-controlled
phase 2 trial
Lancet Oncol 2012;
13: 993–1001
6月23日 ASCO報告(市川)
6月30日 研修医(酒井) Ramucirumab plus docetaxel versus placebo plus docetaxel for
second-line treatment of stage IV non-small-cell lung cancer
after disease progression on platinum-based therapy (REVEL):
a multicentre, double-blind, randomised phase 3 trial
Lancet. 201423;384(9944):665-73
7月7日 ASCO報告(市川)
7月14日 臨床試験勉強会
7月28日 渡邊 Interinstitutional Variation in Management Decisions for Treatment of 4 Common Types of Cancer Ann Intern Med. 2014;161:20-30. 
8月11日 夏目 Young childless women with breast cancer in the UK: a
qualitative study of their fertility-related experiences,
options, and the information given by health professionals
Psycho-Oncology 23: 20–26 (2014)
8月18日 本田 Preoperative chemotherapy for non-small-cell lung cancer:
a systematic review and meta-analysis of individual
participant data
Lancet 2014; 383: 1561–71
8月25日 研修医(北川) Phase III Study Comparing Amrubicin Plus Cisplatin
With Irinotecan Plus Cisplatin in the Treatment of
Extensive-Disease Small-Cell Lung Cancer: JCOG 0509
J Clin Oncol 32:1262-1268. 2014
9月1日 臨床試験勉強会
9月8日 Vitamin, Mineral, and Multivitamin Supplements for the Primary
Prevention of Cardiovascular Disease and Cancer: U.S. Preventive
Services Task Force Recommendation Statement
Ann Intern Med. 2014;160:558-564.
9月22日 太田 Trastuzumab emtansine versus treatment of physician’s
choice for pretreated HER2-positive advanced breast cancer
(TH3RESA): a randomised, open-label, phase 3 trial
Lancet Oncol 2014; 15: 689–99
10月6日 深澤 The Diagnosis and Treatment of Pseudoprogression, Radiation
Necrosis and Brain Tumor Recurrence
Int. J. Mol. Sci. 2014, 15, 11832-11846
10月20日 丹澤 Combination antibiotic therapy with macrolides
improves survival in intubated patients with
community-acquired pneumonia
Intensive Care Med (2010) 36:612–620
10月27日 研修医 Efficacy and safety of maintenance pemetrexed in patients withadvanced nonsquamous non-small cell lung cancer followingpemetrexed plus cisplatin induction treatment: A cross-trialcomparison of two phase III trials Lung Cancer 85 (2014) 408–414
11月10日 坂本 Sorafenib in radioactive iodine-refractory, locally
advanced or metastatic diff erentiated thyroid cancer:
a randomised, double-blind, phase 3 trial
Lancet 2014; 384: 319–28
11月17日 渡邊 New ultrasound techniques for lymph node evaluation World J Gastroenterol 2013 August 14; 19(30): 4850-4860
12月1日 予演会
12月8日 夏目 Methylphenidate hydrochloride improves cognitive
function in patients with advanced cancer and
hypoactive delirium: a prospective clinical study
Rev Psychiatr Neurosci 2005;30(2)
12月15日 本田 Possible differential EGFR-TKI efficacy among exon 19 deletionallocations in EGFR-mutant non-small cell lung cancer Lung Cancer 86 (2014) 213–218
12月22日 研修医(森岡) Safety and activity of alectinib against systemic disease and
brain metastases in patients with crizotinib-resistant
ALK-rearranged non-small-cell lung cancer (AF-002JG):
results from the dose-fi nding portion of a phase 1/2 study
Lancet Oncol 2014; 15: 1119–28
1月19日 太田 First-Line Crizotinib versus Chemotherapy
in ALK-Positive Lung Cancer
N Engl J Med 2014;371:2167-77.
1月26日 丹澤 Frequency of brain metastases in non‑small‑cell lung cancer,and their association with epidermal growth factor receptor mutations Int J Clin Oncol. 2014 Oct 22
2月9日 坂本 Reduced Dose of Salvage-line Regorafenib Monotherapy
for Metastatic Colorectal Cancer in Japan
ANTICANCER RESEARCH 35: 371-378 (2015)
2月16日 渡邊 nab-Paclitaxel Plus Gemcitabine for Metastatic
Pancreatic Cancer: Long-Term Survival From a Phase
III Trial
JNCI J Natl Cancer Inst, 2015, 1–10
2月23日 丸山 Panitumumab–FOLFOX4 Treatment
and RAS Mutations in Colorectal Cancer
N Engl J Med 2013;369:1023-34.
3月9日 市川 Afatinib versus cisplatin-based chemotherapy for EGFR
mutation-positive lung adenocarcinoma (LUX-Lung 3 and
LUX-Lung 6): analysis of overall survival data from two
randomised, phase 3 trials
Lancet Oncol 2015; 16: 141–51
3月16日 Frequency of brain metastases in non‑small‑cell lung cancer,
and their association with epidermal growth factor receptor
mutations
Int J Clin Oncol. 2014 Oct 22

 

コメントは停止中です。